Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program
Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program
复制标题
DOI：
10.1016/j.jsat.2016.12.014
复制
发表时间：
2017-04-01
影响因子：
3.9
通讯作者：
Tetrault, Jeanette M.
中科院分区：
文献类型：
--
作者：
Butner, Jenna L.;Gupta, Neil;Tetrault, Jeanette M.
随着直接作用抗病毒药物(DAA)或所有口服丙型肝炎病毒治疗方案的出现，为参加阿片类药物治疗计划(OW)的注射吸毒者(PWID)提供了一个很好的机会。这项在常规临床护理的背景下进行的回顾性研究探索了在登记参加OTP的PWID中使用DAA治疗丙型肝炎的结果。我们的研究表明，我们的第一批75名接受DAA治疗的患者的治疗结果几乎与普通人群中的患者相同。在完成治疗的患者中，98%获得了持续的病毒学应答，有10名患者失去了随访。99%的患者坚持接受丙型肝炎病毒治疗。23%的患者持续使用药物，但这并没有改变丙型肝炎病毒的治疗结果。在动态口服液中现场应用DAA治疗丙型肝炎是可行的。(C)2017 Elsevier Inc.保留所有权利。
With the advent of the direct acting antivirals (DAA), or all oral HCV treatment regimens, there exists a great opportunity to provide HCV treatment to people who inject drugs (PWID) enrolled in an opioid treatment program (OW). This retrospective study conducted in the context of routine clinical care explores the outcomes of HCV treatment with DAAs in PWID enrolled in an OTP. Our study showed treatment outcomes among our first 75 patients treated with DAAs were nearly equivalent to patients in the general population. Ninety-eight percent of patients completing treatment obtained a sustained virologic response, with 10 patients lost to follow-up. Ninety-nine percent of patients adhered to HCV treatment. Ongoing drug use occurred in 23% of patients, however this did not alter HCV treatment outcomes. Treating HCV infection with DAAs in PWID onsite in an OTP is feasible. (C) 2017 Elsevier Inc. All rights reserved.